Trends in the indications for and short-term outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy

Eliza W. Beal; Ahmed Ahmed; Travis Grotz; Jennifer Leiting; Keith F. Fournier; Andrew J. Lee; Sean Dineen; Sophie Dessureault; Joel M. Baumgartner; Jula Veerapong; Callisia Clarke; Erin Strong; Shishir K. Maithel; Mohammad Y. Zaidi; Sameer Patel; Vikrom Dhar; Ryan Hendrix; Laura Lambert; Fabian Johnston; Nadege Fackche; Mustafa Raoof; Christopher LaRocca; Sean Ronnekleiv-Kelly; Courtney Pokrzywa; Timothy M. Pawlik; Sherif Abdel-Misih; Jordan M. Cloyd

doi:10.1016/j.amjsurg.2019.09.017

Trends in the indications for and short-term outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy

Eliza W. Beal
, Ahmed Ahmed
, Travis Grotz
, Jennifer Leiting
, Keith F. Fournier
, Andrew J. Lee
, Sean Dineen
, Sophie Dessureault
, Joel M. Baumgartner
, Jula Veerapong
, Callisia Clarke
, Erin Strong
, Shishir K. Maithel
, Mohammad Y. Zaidi
, Sameer Patel
, Vikrom Dhar
, Ryan Hendrix
, Laura Lambert
, Fabian Johnston
, Nadege Fackche

Mustafa Raoof, Christopher LaRocca, Sean Ronnekleiv-Kelly, Courtney Pokrzywa, Timothy M. Pawlik, Sherif Abdel-Misih, Jordan M. Cloyd

Surgery

Ohio State University
Mayo Clinic Rochester, MN
University of Texas MD Anderson Cancer Center
Moffitt Cancer Center
University of California at San Diego
Medical College of Wisconsin
Emory University
University of Cincinnati
University of Massachusetts Medical School
Johns Hopkins University
City of Hope National Med Center
University of Wisconsin-Madison

Research output: Contribution to journal › Article › peer-review

44 Scopus citations

Abstract

Background: Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is an increasingly utilized strategy for patients with peritoneal surface malignancies (PSM). Methods: The US HIPEC Collaborative was retrospectively reviewed to compare the indications and perioperative outcomes of patients who underwent CRS ± HIPEC between 2000 and 2012 (P1) versus 2013–2017 (P2). Results: Among 2,364 patients, 39% were from P1 and 61% from P2. The most common primary site was appendiceal (64%) while the median PCI was 13 and most patients had CCR 0 (60%) or 1 (25%). Over time, median estimated blood loss, need for transfusion, and length of hospital stay decreased. While the incidence of any (55% vs. 57%; p = 0.426) and Clavien III/IV complications did not change over time, there was a decrease in 90-day mortality (5% vs. 3%; p = 0.045). Conclusion: CRS-HIPEC is increasingly performed for PSM at high-volume centers. Despite improvements in some perioperative outcomes and a reduction in postoperative mortality, morbidity rates remain high.

Original language	English
Pages (from-to)	478-483
Number of pages	6
Journal	American Journal of Surgery
Volume	219
Issue number	3
DOIs	https://doi.org/10.1016/j.amjsurg.2019.09.017
State	Published - Mar 2020

Keywords

Cytoreductive surgery
Hyperthermic intraperitoneal chemotherapy

Access to Document

10.1016/j.amjsurg.2019.09.017

Cite this

Beal, E. W., Ahmed, A., Grotz, T., Leiting, J., Fournier, K. F., Lee, A. J., Dineen, S., Dessureault, S., Baumgartner, J. M., Veerapong, J., Clarke, C., Strong, E., Maithel, S. K., Zaidi, M. Y., Patel, S., Dhar, V., Hendrix, R., Lambert, L., Johnston, F., ... Cloyd, J. M. (2020). Trends in the indications for and short-term outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. American Journal of Surgery, 219(3), 478-483. https://doi.org/10.1016/j.amjsurg.2019.09.017

@article{eacdc72941784886a0cd66bd030ec4c2,

title = "Trends in the indications for and short-term outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy",

abstract = "Background: Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is an increasingly utilized strategy for patients with peritoneal surface malignancies (PSM). Methods: The US HIPEC Collaborative was retrospectively reviewed to compare the indications and perioperative outcomes of patients who underwent CRS ± HIPEC between 2000 and 2012 (P1) versus 2013{\textendash}2017 (P2). Results: Among 2,364 patients, 39\% were from P1 and 61\% from P2. The most common primary site was appendiceal (64\%) while the median PCI was 13 and most patients had CCR 0 (60\%) or 1 (25\%). Over time, median estimated blood loss, need for transfusion, and length of hospital stay decreased. While the incidence of any (55\% vs. 57\%; p = 0.426) and Clavien III/IV complications did not change over time, there was a decrease in 90-day mortality (5\% vs. 3\%; p = 0.045). Conclusion: CRS-HIPEC is increasingly performed for PSM at high-volume centers. Despite improvements in some perioperative outcomes and a reduction in postoperative mortality, morbidity rates remain high.",

keywords = "Cytoreductive surgery, Hyperthermic intraperitoneal chemotherapy",

author = "Beal, \{Eliza W.\} and Ahmed Ahmed and Travis Grotz and Jennifer Leiting and Fournier, \{Keith F.\} and Lee, \{Andrew J.\} and Sean Dineen and Sophie Dessureault and Baumgartner, \{Joel M.\} and Jula Veerapong and Callisia Clarke and Erin Strong and Maithel, \{Shishir K.\} and Zaidi, \{Mohammad Y.\} and Sameer Patel and Vikrom Dhar and Ryan Hendrix and Laura Lambert and Fabian Johnston and Nadege Fackche and Mustafa Raoof and Christopher LaRocca and Sean Ronnekleiv-Kelly and Courtney Pokrzywa and Pawlik, \{Timothy M.\} and Sherif Abdel-Misih and Cloyd, \{Jordan M.\}",

note = "Publisher Copyright: {\textcopyright} 2019 Elsevier Inc.",

year = "2020",

month = mar,

doi = "10.1016/j.amjsurg.2019.09.017",

language = "English",

volume = "219",

pages = "478--483",

journal = "American Journal of Surgery",

issn = "0002-9610",

number = "3",

}

Beal, EW, Ahmed, A, Grotz, T, Leiting, J, Fournier, KF, Lee, AJ, Dineen, S, Dessureault, S, Baumgartner, JM, Veerapong, J, Clarke, C, Strong, E, Maithel, SK, Zaidi, MY, Patel, S, Dhar, V, Hendrix, R, Lambert, L, Johnston, F, Fackche, N, Raoof, M, LaRocca, C, Ronnekleiv-Kelly, S, Pokrzywa, C, Pawlik, TM, Abdel-Misih, S & Cloyd, JM 2020, 'Trends in the indications for and short-term outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy', American Journal of Surgery, vol. 219, no. 3, pp. 478-483. https://doi.org/10.1016/j.amjsurg.2019.09.017

TY - JOUR

T1 - Trends in the indications for and short-term outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy

AU - Beal, Eliza W.

AU - Ahmed, Ahmed

AU - Grotz, Travis

AU - Leiting, Jennifer

AU - Fournier, Keith F.

AU - Lee, Andrew J.

AU - Dineen, Sean

AU - Dessureault, Sophie

AU - Baumgartner, Joel M.

AU - Veerapong, Jula

AU - Clarke, Callisia

AU - Strong, Erin

AU - Maithel, Shishir K.

AU - Zaidi, Mohammad Y.

AU - Patel, Sameer

AU - Dhar, Vikrom

AU - Hendrix, Ryan

AU - Lambert, Laura

AU - Johnston, Fabian

AU - Fackche, Nadege

AU - Raoof, Mustafa

AU - LaRocca, Christopher

AU - Ronnekleiv-Kelly, Sean

AU - Pokrzywa, Courtney

AU - Pawlik, Timothy M.

AU - Abdel-Misih, Sherif

AU - Cloyd, Jordan M.

PY - 2020/3

Y1 - 2020/3

N2 - Background: Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is an increasingly utilized strategy for patients with peritoneal surface malignancies (PSM). Methods: The US HIPEC Collaborative was retrospectively reviewed to compare the indications and perioperative outcomes of patients who underwent CRS ± HIPEC between 2000 and 2012 (P1) versus 2013–2017 (P2). Results: Among 2,364 patients, 39% were from P1 and 61% from P2. The most common primary site was appendiceal (64%) while the median PCI was 13 and most patients had CCR 0 (60%) or 1 (25%). Over time, median estimated blood loss, need for transfusion, and length of hospital stay decreased. While the incidence of any (55% vs. 57%; p = 0.426) and Clavien III/IV complications did not change over time, there was a decrease in 90-day mortality (5% vs. 3%; p = 0.045). Conclusion: CRS-HIPEC is increasingly performed for PSM at high-volume centers. Despite improvements in some perioperative outcomes and a reduction in postoperative mortality, morbidity rates remain high.

AB - Background: Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is an increasingly utilized strategy for patients with peritoneal surface malignancies (PSM). Methods: The US HIPEC Collaborative was retrospectively reviewed to compare the indications and perioperative outcomes of patients who underwent CRS ± HIPEC between 2000 and 2012 (P1) versus 2013–2017 (P2). Results: Among 2,364 patients, 39% were from P1 and 61% from P2. The most common primary site was appendiceal (64%) while the median PCI was 13 and most patients had CCR 0 (60%) or 1 (25%). Over time, median estimated blood loss, need for transfusion, and length of hospital stay decreased. While the incidence of any (55% vs. 57%; p = 0.426) and Clavien III/IV complications did not change over time, there was a decrease in 90-day mortality (5% vs. 3%; p = 0.045). Conclusion: CRS-HIPEC is increasingly performed for PSM at high-volume centers. Despite improvements in some perioperative outcomes and a reduction in postoperative mortality, morbidity rates remain high.

KW - Cytoreductive surgery

KW - Hyperthermic intraperitoneal chemotherapy

UR - https://www.scopus.com/pages/publications/85072399201

U2 - 10.1016/j.amjsurg.2019.09.017

DO - 10.1016/j.amjsurg.2019.09.017

M3 - Article

C2 - 31558307

AN - SCOPUS:85072399201

SN - 0002-9610

VL - 219

SP - 478

EP - 483

JO - American Journal of Surgery

JF - American Journal of Surgery

IS - 3

ER -

Trends in the indications for and short-term outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this